NCT01850602View on ClinicalTrials.gov

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

PHASE3CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

April 23, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 10, 2013

Conditions
HemodialysisHyperphosphatemia
Interventions
DRUG

PA21

DRUG

Sevelamer hydrochloride

Trial Locations (1)

Unknown

Multiple Locations

Sponsors
All Listed Sponsors
lead

Kissei Pharmaceutical Co., Ltd.

INDUSTRY